-transparent.png){kind=logo}
A series of experiments was performed to investigate the effects of corticotropin-releasing factor (CRF) on the amplitude of the acoustic startle response (ASR) in rats. Intracerebroventricular (ICV) administration of 1 microgram rat CRF significantly potentiated acoustic startle amplitude; these effects were reversed in a dose-dependent manner by pretreatment with the benzodiazepine chlordiazepoxide (CDP). Doses of CDP that antagonized CRF-potentiated ASR did not lower startle baseline or antagonize amphetamine- or strychnine-potentiated ASR. These results suggest that CRF has "anxiogenic" properties and may serve as a neuroendocrine modulator of stress-enhanced behaviors.
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
June 1992,
The Journal of neuroscience : the official journal of the Society for Neuroscience,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
December 1994,
Brain research,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
November 2021,
Genes, brain, and behavior,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
January 1985,
Psychopharmacology,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
November 2003,
Psychopharmacology,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
May 2002,
Psychopharmacology,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
February 1984,
The Journal of clinical investigation,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
December 1989,
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
December 1997,
Brain research,
N R Swerdlow, and
M A Geyer, and
W W Vale, and
G F Koob
April 1998,
Psychopharmacology,
